| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8829122 | Revista Mexicana de Urología | 2016 | 8 Pages |
Abstract
Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different in vitro, as well as in vivo, studies. The present study analyzed the main benefits of silodosin in phase iii clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase iv trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
A. Alcántara Montero,